SAN FRANCISCO — Janus kinase (JAK) inhibitors appeared to be a safe, effective option for treating inflammatory bowel disease (IBD) in older adults, according to
“We at the American Journal of Public Health have no interest in following the president’s prohibitions on language.” — Georges Benjamin, MD, executive director of
Teres is a critical care physician. Sorum is a professor emeritus of internal medicine and pediatrics. Strosberg is a professor emeritus of healthcare policy and
The U.S. winter virus season is in full force, and by one measure is the most intense in 15 years. One indicator of flu activity
LOS ANGELES — In the PRESTIGE-AF trial, survivors of intracerebral hemorrhage (ICH) had good protection against future ischemic events using direct oral anticoagulants (DOACs) —
The FDA approved AbbVie and Pfizer’s drug Emblaveo in combination with an older antibiotic to treat complicated intra-abdominal infections. AbbVie, which owns the US commercial
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
LOS ANGELES — The HOPE trial made another case for extending the therapeutic window for IV thrombolysis in acute ischemic stroke, potentially widening the pool
The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted
SAN FRANCISCO — More adults with moderate-to-severe Crohn’s disease (CD) reached clinical remission after 6 months on risankizumab (Skyrizi) versus ustekinumab (Stelara), according to a